Show simple item record

An Isotoxic Planning Comparison Study for Stage II-III Non-small Cell Lung Cancer: Is Intensity-modulated Radiotherapy the Answer?

dc.contributor.authorWarren, Mark
dc.contributor.authorWebster, G
dc.contributor.authorRyder, W David J
dc.contributor.authorRowbottom, Carl G
dc.contributor.authorFaivre-Finn, Corinne
dc.date.accessioned2014-05-30T08:47:14Z
dc.date.available2014-05-30T08:47:14Z
dc.date.issued2014-05-01
dc.identifier.citationAn Isotoxic Planning Comparison Study for Stage II-III Non-small Cell Lung Cancer: Is Intensity-modulated Radiotherapy the Answer? 2014: Clin Oncolen
dc.identifier.issn1433-2981
dc.identifier.pmid24793504
dc.identifier.doi10.1016/j.clon.2014.03.011
dc.identifier.urihttp://hdl.handle.net/10541/317652
dc.description.abstractRecent clinical series suggest that treating patients with isotoxic twice-daily radiotherapy may be beneficial. This dosimetric planning study compared the use of intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DRT) to deliver isotoxic treatment for non-small cell lung cancer (NSCLC) patients.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Clinical oncology (Royal College of Radiologists (Great Britain))en
dc.titleAn Isotoxic Planning Comparison Study for Stage II-III Non-small Cell Lung Cancer: Is Intensity-modulated Radiotherapy the Answer?en
dc.typeArticleen
dc.contributor.departmentChristie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalClinical Oncologyen
html.description.abstractRecent clinical series suggest that treating patients with isotoxic twice-daily radiotherapy may be beneficial. This dosimetric planning study compared the use of intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DRT) to deliver isotoxic treatment for non-small cell lung cancer (NSCLC) patients.


Files in this item

This item appears in the following Collection(s)

Show simple item record